Advertisement
Advertisement
U.S. markets open in 8 hours 49 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ZLAB Dec 2022 80.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.51000.0000 (0.00%)
As of 12:31PM EDT. Market open.
Advertisement
Full screen
Previous Close2.5100
Open2.5100
Bid0.0000
Ask0.0000
Strike80.00
Expire Date2022-12-16
Day's Range2.5100 - 2.5100
Contract RangeN/A
Volume80
Open InterestN/A
  • Bloomberg

    Latest Push by Chinese Firms to Avoid Delistings Falls Short

    (Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark

  • American City Business Journals

    A Chinese pharma plans fast expansion of Cambridge HQ

    Shanghai-based Zai Lab Limited is looking to become an international pharma giant, using its new U.S. headquarters in Cambridge as a home base.

  • Benzinga

    Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment

    Seagen Inc (NASDAQ: SGEN) and Zai Lab Limited (NASDAQ: ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the first and only ADC approved in the U.S. for treating adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The collaboration supports regional patient enrollment for InnovaTV 301

Advertisement
Advertisement